BiotechTube

Zalviso™ 15 mcg

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate-to-severe Acute Pain

Conditions

Moderate-to-severe Acute Pain

Trial Timeline

Sep 28, 2016 → May 5, 2017

NCT ID
NCT02662764

About Zalviso™ 15 mcg

Zalviso™ 15 mcg is a phase 3 stage product being developed by Talphera for Moderate-to-severe Acute Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02662764. Target conditions include Moderate-to-severe Acute Pain.

What happened to similar drugs?

2 of 8 similar drugs in Moderate-to-severe Acute Pain were approved

Approved (2) Terminated (0) Active (6)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
🔄SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
🔄Indacaterol + ControlNovartisPhase 3
🔄Dupilumab + PlaceboSanofiPhase 3
✅dupilumabSanofiApproved
🔄PonesimodVanda PharmaceuticalsPhase 3
🔄sufentanil sublingual tablet 30 mcgTalpheraPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02662764Phase 3Completed

Competing Products

13 competing products in Moderate-to-severe Acute Pain

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
SHR-1314Jiangsu Hengrui MedicinePhase 1
25
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
36
Indacaterol + ControlNovartisPhase 3
40
DeucravacitinibBristol Myers SquibbPre-clinical
33
Dupilumab + PlaceboSanofiPhase 3
40
dupilumabSanofiApproved
43
dupilumabSanofiPre-clinical
26
PonesimodVanda PharmaceuticalsPhase 3
37
sufentanil sublingual tablet 30 mcgTalpheraPhase 3
30
sufentanil sublingual 30 mcg tabletTalpheraPhase 3
30